HER2 Mutations Identified as Treatment Targets in Patients With HER2-Negative Breast Cancer
Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.